Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, Status and Forecast 2024-2031

Report ID: 922384 | Published Date: Jan 2025 | No. of Page: 106 | Base Year: 2024 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Therapeutics
        1.2.3 Diagnostics
    1.3 Market by Application
        1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinic
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Perspective (2016-2027)
    2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Growth Trends by Regions
        2.2.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Share by Regions (2016-2021)
        2.2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027)
    2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Dynamic
        2.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends
        2.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
        2.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
        2.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue
        3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue (2016-2021)
        3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Players (2016-2021)
    3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue
    3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio
        3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2020
    3.5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Area Served
    3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
    3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Type
    4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Type (2016-2021)
    4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027)

5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Application
    5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Application (2016-2021)
    5.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
    6.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
        6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
        6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
        6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
    6.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
        6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
        6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
        6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
    6.4 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
        6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
        6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
    7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
        7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
        7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
        7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
    7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
        7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
        7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
        7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
    7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
        7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
        7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
    8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
        8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
        8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region
        8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
    9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
        9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
        9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
        9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
    9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
        9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
        9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
        9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
    9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
        9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
        9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
    10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
        10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
        10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
        10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Siemens Healthcare
        11.1.1 Siemens Healthcare Company Details
        11.1.2 Siemens Healthcare Business Overview
        11.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.1.4 Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.1.5 Siemens Healthcare Recent Development
    11.2 Celerion
        11.2.1 Celerion Company Details
        11.2.2 Celerion Business Overview
        11.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.2.4 Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.2.5 Celerion Recent Development
    11.3 ZyVersa Therapeutics, Inc.
        11.3.1 ZyVersa Therapeutics, Inc. Company Details
        11.3.2 ZyVersa Therapeutics, Inc. Business Overview
        11.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.3.4 ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.3.5 ZyVersa Therapeutics, Inc. Recent Development
    11.4 Cisbio
        11.4.1 Cisbio Company Details
        11.4.2 Cisbio Business Overview
        11.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.4.4 Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.4.5 Cisbio Recent Development
    11.5 Regeneron Pharmaceuticals, Inc.
        11.5.1 Regeneron Pharmaceuticals, Inc. Company Details
        11.5.2 Regeneron Pharmaceuticals, Inc. Business Overview
        11.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.5.4 Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.5.5 Regeneron Pharmaceuticals, Inc. Recent Development
    11.6 BioPredictive
        11.6.1 BioPredictive Company Details
        11.6.2 BioPredictive Business Overview
        11.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.6.4 BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.6.5 BioPredictive Recent Development
    11.7 Echosens
        11.7.1 Echosens Company Details
        11.7.2 Echosens Business Overview
        11.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.7.4 Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.7.5 Echosens Recent Development
    11.8 Genfit
        11.8.1 Genfit Company Details
        11.8.2 Genfit Business Overview
        11.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.8.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.8.5 Genfit Recent Development
    11.9 Enterome
        11.9.1 Enterome Company Details
        11.9.2 Enterome Business Overview
        11.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.9.4 Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.9.5 Enterome Recent Development
    11.10 NGM Biopharmaceuticals
        11.10.1 NGM Biopharmaceuticals Company Details
        11.10.2 NGM Biopharmaceuticals Business Overview
        11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
        11.10.4 NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
        11.10.5 NGM Biopharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Therapeutics
    Table 3. Key Players of Diagnostics
    Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2016-2021)
    Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
    Table 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends
    Table 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
    Table 12. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
    Table 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints
    Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players (2016-2021)
    Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2020)
    Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
    Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
    Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
    Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Siemens Healthcare Company Details
    Table 62. Siemens Healthcare Business Overview
    Table 63. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 64. Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 65. Siemens Healthcare Recent Development
    Table 66. Celerion Company Details
    Table 67. Celerion Business Overview
    Table 68. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 69. Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 70. Celerion Recent Development
    Table 71. ZyVersa Therapeutics, Inc. Company Details
    Table 72. ZyVersa Therapeutics, Inc. Business Overview
    Table 73. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 74. ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 75. ZyVersa Therapeutics, Inc. Recent Development
    Table 76. Cisbio Company Details
    Table 77. Cisbio Business Overview
    Table 78. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 79. Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 80. Cisbio Recent Development
    Table 81. Regeneron Pharmaceuticals, Inc. Company Details
    Table 82. Regeneron Pharmaceuticals, Inc. Business Overview
    Table 83. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 84. Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 85. Regeneron Pharmaceuticals, Inc. Recent Development
    Table 86. BioPredictive Company Details
    Table 87. BioPredictive Business Overview
    Table 88. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 89. BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 90. BioPredictive Recent Development
    Table 91. Echosens Company Details
    Table 92. Echosens Business Overview
    Table 93. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 94. Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 95. Echosens Recent Development
    Table 96. Genfit Company Details
    Table 97. Genfit Business Overview
    Table 98. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 99. Genfit Recent Development
    Table 100. Enterome Company Details
    Table 101. Enterome Business Overview
    Table 102. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 103. Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 104. Enterome Recent Development
    Table 105. NGM Biopharmaceuticals Company Details
    Table 106. NGM Biopharmaceuticals Business Overview
    Table 107. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
    Table 108. NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
    Table 109. NGM Biopharmaceuticals Recent Development
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type: 2020 VS 2027
    Figure 2. Therapeutics Features
    Figure 3. Diagnostics Features
    Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2020 VS 2027
    Figure 5. Hospital Case Studies
    Figure 6. Clinic Case Studies
    Figure 7. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered
    Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2027
    Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
    Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players in 2020
    Figure 13. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2020
    Figure 14. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2020
    Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
    Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027)
    Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
    Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
    Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
    Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
    Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
    Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
    Figure 27. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Nordic Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
    Figure 35. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
    Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2016-2027)
    Figure 37. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
    Figure 45. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
    Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
    Figure 47. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
    Figure 51. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
    Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
    Figure 53. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Siemens Healthcare Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 57. Celerion Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 58. ZyVersa Therapeutics, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 59. Cisbio Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 60. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 61. BioPredictive Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 62. Echosens Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 63. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 64. Enterome Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 65. NGM Biopharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Frequently Asked Questions
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Marine Drug

The drug obtained from marine organisms which are being conventionally used like shark and cod-li ... Read More